✦ LIBER ✦

Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis

✍ Scribed by R Fleischmann

Book ID: 120708068
Publisher: BioMed Central
Year: 2003
Tongue: English
Weight: 554 KB
Volume: 5
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar807

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interleukin-6 receptor inhibition with t

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

Indirect Comparison of Tocilizumab and O

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

✍ Gert J.D. Bergman; Marc C. Hochberg; Maarten Boers; Neil Wintfeld; Adrian Kielho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 595 KB

Cost-Effectiveness Analysis of Biologica

Cost-Effectiveness Analysis of Biological Disease-Modifying Antirheumatic Drugs in the Treatment of Russian Patients with Rheumatoid Arthritis Who Failed Previous Anti-Tnf-Alfa Therapy

✍ Ryazhenov, V.V.; Emchenko, I.V. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Response-Driven Combination Therapy with

Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Use

✍ Susanna M. Proudman; Helen I. Keen; Lisa K. Stamp; Anita T.Y. Lee; Fiona Goldbla 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 654 KB

Serum levels of CXCL13 are associated wi

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs

✍ Manzo, A.; Bugatti, S.; Benaglio, F.; Vitolo, B.; Klersy, C.; Montecucco, C.; Ca 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 72 KB

Phase III, multicenter, open-label, long

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs

✍ Takeuchi, Tsutomu; Matsubara, Tsukasa; Urata, Yukitomo; Suematsu, Eiichi; Ohta, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 250 KB